Related by context. All words. (Click for frequent words.) 73 recurrent NSCLC 72 stage IIIb IV 71 non squamous NSCLC 70 metastatic colorectal 70 stage IIIB IV 70 metastatic gastric 69 nonsmall cell lung cancer 69 gastrointestinal stromal tumor GIST 69 squamous non 69 refractory chronic lymphocytic 68 unresectable locally advanced 68 tumors GIST 68 erlotinib Tarceva ® 68 advanced metastatic renal 68 gastrointestinal stromal tumors 68 sorafenib tablets 67 gastrointestinal stromal tumors GIST 67 metastatic renal cell carcinoma 67 metastatic GIST 67 gefitinib Iressa 67 metastatic pancreatic 66 unresectable 66 Hepatocellular Carcinoma HCC 66 gemcitabine chemotherapy 66 recurrent glioblastoma multiforme 66 squamous 66 metastatic renal cell 66 metastatic breast 66 nonsquamous 66 metastatic castration resistant 66 stage IIIB 66 lymphoma CTCL 66 unresectable stage 66 cell lung cancer 66 malignant pleural mesothelioma 66 TTF Therapy 65 HRPC ovarian cancer 65 fallopian tube carcinoma 65 metastatic castrate resistant 65 subependymal giant cell 65 hepatocellular cancer 65 recurrent colorectal cancer 65 cediranib 65 unresectable tumors 65 basal cell carcinoma BCC 65 sunitinib Sutent 65 metastatic neuroendocrine tumors 65 metastatic malignant melanoma 65 sorafenib Nexavar 65 cisplatin resistant 65 gemcitabine carboplatin 65 HER2 positive metastatic breast 65 docetaxel Taxotere ® 65 Nexavar sorafenib 65 AVASTIN 65 mRCC 65 biliary tract cancer 65 FOLFOX6 65 nonmetastatic 65 advanced unresectable 65 stage IIIA 65 metastatic malignant 64 carcinoma HCC 64 5 fluorouracil leucovorin 64 dasatinib Sprycel 64 metastatic carcinoma 64 myelodysplastic myeloproliferative diseases 64 metastatic hormone refractory 64 gastrointestinal stromal tumor 64 HGS ETR1 mapatumumab 64 peritoneal carcinomatosis 64 pancreatic adenocarcinoma 64 EGFR mutation positive 64 5 FU leucovorin 64 systemic anaplastic large 64 dasatinib Sprycel ® 64 Hurthle cell 64 Platinol ® cisplatin 64 chemotherapy cisplatin 64 bladder ovarian 64 Tarceva erlotinib 64 cutaneous T cell 64 Gliadel Wafer 64 differentiating squamous 64 ZOLINZA 64 underwent surgical resection 64 hypereosinophilic syndrome 64 R sorafenib tablets 64 evaluating picoplatin 64 bevacizumab Avastin ® 64 lung malignant melanoma 64 vincristine doxorubicin 64 Squamous 64 lung pancreatic 64 FOLFOX4 64 ZACTIMA 64 situ CIS 63 fluoropyrimidine 63 superficial basal cell carcinoma 63 relapsed SCLC 63 opioid induced constipation OIC 63 prostate carcinoma 63 metastatic HRPC 63 metastatic CRC 63 anthracycline taxane 63 Amrubicin 63 leukemia AML 63 pancreatic NET 63 non resectable 63 allogeneic bone marrow 63 myelofibrosis polycythemia vera 63 Kit CD# positive 63 resistant hormone refractory 63 recurrent metastatic 63 squamous histology 63 minimally symptomatic 63 radiofrequency ablation RFA 63 BRIM2 63 Nexavar ® 63 advanced medullary thyroid 63 cutaneous T 63 Surgical resection 63 cell carcinoma RCC 63 kidney urologic 63 Naive Patients 63 LHRH receptor positive 63 resectable 63 Ixempra 63 complement inhibitor eculizumab 63 adriamycin 63 Doxil ® 63 unstable angina UA 63 neoadjuvant therapy 63 pancreatic carcinoma 63 cancer mCRC 63 pain palliation 63 docetaxel Taxotere R 63 colorectal cancer liver metastases 63 unresectable liver cancer 63 EGFR TKI 63 ACTEMRA TM 63 metastatic HER2 negative 63 hormone refractory metastatic prostate 63 neuroendocrine cancers 63 imatinib Gleevec ® 63 FOLFIRI alone 63 trastuzumab DM1 T DM1 63 preoperative staging 62 Vidaza ® 62 gemcitabine Gemzar 62 small lymphocytic lymphoma 62 completely resected 62 histologies 62 metastatic bladder 62 differentiated thyroid 62 evaluating tivozanib 62 hematological diseases 62 docetaxel chemotherapy 62 nilotinib Tasigna ® 62 metastatic renal 62 relapsing remitting MS RRMS 62 Cell Lung Cancer 62 FUSILEV enhances 62 tumor xenograft models 62 Basal cell 62 Tarceva TM 62 Fludarabine 62 vinca alkaloids 62 lung ovarian 62 medically inoperable 62 Erlotinib 62 refractory multiple myeloma 62 cisplatin chemotherapy 62 BRIM3 62 cetuximab Erbitux R 62 FOLFIRI 62 papillary renal cell carcinoma 62 cell lymphoma CTCL 62 Folfox 62 anthracycline containing 62 Xelox 62 leukemia CLL 62 standard chemotherapy regimens 62 oral clodronate 62 NMIBC 62 CYT# potent vascular disrupting 62 Nexavar tablets 62 acute myeloid 62 concurrent chemoradiation 62 recurrent GBM 62 Hormone Refractory Prostate Cancer 62 clinically localized prostate 62 Torisel 62 refractory NSCLC 62 commercialize deforolimus 62 Pemetrexed 62 leukemia APL 62 metastatic RCC 62 Bayer HealthCare Onyx Pharmaceuticals 62 MAGE A3 ASCI 62 sunitinib Sutent ® 62 Gorlin syndrome 62 Advanced Renal Cell 62 Peginterferon alfa 2b 62 pertuzumab 62 essential thrombocythemia ET 62 Accelerated Partial Breast Irradiation 62 metastatic colorectal cancer 62 Acute Myeloid Leukemia AML 62 cetuximab Erbitux ® 62 taxane chemotherapy 62 VELCADE melphalan 62 recurrent malignant glioma 62 Ribavirin causes 62 sirolimus stent 62 epithelial tumors 62 doublet chemotherapy 62 prostate cancer HRPC 62 Metastatic Colorectal Cancer 62 Class IIIB IV 61 BRAF inhibitor 61 intravesical infusion therapy 61 interferon gamma 1b 61 KRAS wild 61 metastatic NSCLC 61 relapsed MM 61 esophageal candidiasis 61 Fludara ® 61 hepatic metastases 61 Gleevec resistant 61 Aflibercept 61 sorafenib Nexavar ® 61 hepatorenal syndrome 61 adjuvant radiotherapy 61 Camptosar ® 61 seminoma 61 carcinoid 61 Lenalidomide 61 NSCLC 61 fallopian tube cancers 61 NSCLC tumors 61 thalidomide Thalomid 61 oral ridaforolimus 61 previously untreated follicular 61 pediatric acute lymphoblastic 61 radiation chemoradiation 61 relapsed multiple myeloma 61 imetelstat GRN#L 61 Actemra tocilizumab 61 Paraplatin ® carboplatin 61 Gemzar ® 61 dacarbazine 61 chronic myeloid 61 irinotecan chemotherapy 61 irinotecan doxorubicin oxaliplatin paclitaxel 61 malignant ascites 61 galiximab 61 superficial bladder cancer 61 paclitaxel carboplatin 61 atypical Hemolytic Uremic Syndrome 61 Anaplastic 61 mTOR inhibitor 61 idiopathic pulmonary fibrosis IPF 61 chemoembolization 61 leukemia multiple myeloma 61 carboplatin paclitaxel 61 standard chemotherapy regimen 61 Cutaneous T 61 non resectable metastatic 61 SIR Spheres 61 p# biomarker 61 unresectable hepatocellular carcinoma HCC 61 Glioblastoma Multiforme GBM 61 temsirolimus 61 hyperplasia BPH 61 demethylating agent 61 assessing T DM1 61 cetuximab Erbitux 61 paraganglioma 61 KRAS mutations occur 61 trabectedin 61 ongoing Phase 1b 61 doxorubicin HCl liposome injection 61 transplantation HCT 61 K ras mutations 61 colorectal liver metastases 61 pancreatic neuroendocrine tumors 61 deCODE ProstateCancer TM 61 metastatic androgen independent 61 anaplastic astrocytoma AA 61 axitinib 61 indolent follicular non 61 Taxotere ® 61 castrate resistant prostate cancer 61 Her2/neu 61 NovoTTF 61 Wafer polifeprosan 61 temsirolimus Torisel 61 KRAS mutation 61 malignant polyps 61 brand ciclesonide HFA 61 Gleevec imatinib mesylate 61 ANCA associated 61 recurrent glioblastoma multiforme GBM 61 CDK cyclin dependent 61 iniparib 61 prostate cancer CRPC 61 histone deacetylase HDAC inhibitor 61 endocrine therapies 61 GW# [003] 61 infusional 5-FU/LV 61 deCODE AF TM 61 benign neoplasms 61 HBeAg negative 61 BR.# 61 dacarbazine DTIC 61 systemic ALCL 61 EGFR expressing mCRC 61 hematologic disorders 61 metastatic kidney 61 liposomal doxorubicin 61 chemoradiation therapy 61 follicular lymphoma FL 61 ovarian endometrial 61 cell carcinoma 61 keloid scarring 61 Paraplatin ® 61 chronic lymphocytic leukemia CLL 61 Hycamtin 61 Certolizumab pegol 61 Soft Tissue Sarcoma 61 IV NSCLC 61 Pfizer Sutent 61 Tamibarotene 61 advanced pancreatic neuroendocrine 61 liver metastases 61 smoldering multiple myeloma 61 relapsed ovarian cancer 61 Oral Fingolimod 61 ovarian esophageal 61 lenalidomide Revlimid R 61 minimally symptomatic metastatic castrate 61 advanced hepatocellular carcinoma 60 bevacizumab Avastin 60 polycythemia vera PV 60 recurrent glioblastoma 60 Relapsed Refractory 60 Stage IIIb 60 Cloretazine 60 prostate carcinomas 60 alpha1 antitrypsin deficiency 60 trastuzumab Herceptin ® 60 Follicular Lymphoma 60 metastatic lung cancer 60 B CLL 60 Jevtana 60 vandetanib 60 metastatic HER2 positive 60 refractory metastatic 60 radiation sensitizer 60 vinca alkaloid 60 lymphocytic leukemia 60 androgen independent 60 GISTs 60 chlorambucil 60 plus gemcitabine 60 mucinous 60 Chronic Myelogenous Leukemia CML 60 haematologic 60 NASH Huntington 60 resectable pancreatic cancer 60 modified glutathione analog 60 squamous cell lung cancer 60 evaluating T DM1 60 IgG1 monoclonal antibody 60 Wegener granulomatosis 60 Dasatinib 60 imatinib mesylate 60 colon esophageal 60 refractory acute myeloid 60 hepatocellular carcinoma HCC 60 vorinostat 60 refractory chronic myeloid 60 Halaven 60 Lung transplantation 60 alkylating agent 60 dacarbazine chemotherapy 60 imatinib Gleevec 60 forodesine 60 prostate adenocarcinoma 60 paclitaxel cisplatin 60 Myelodysplastic Syndrome 60 antibody MAb 60 Myelodysplastic Syndromes 60 sunitinib malate 60 carcinoid tumors 60 acute GvHD 60 refractory ovarian cancer 60 plus dexamethasone 60 underwent resection 60 aneurysms AAA 60 Genasense ® 60 hypervascular tumors 60 ELOXATIN 60 bevacizumab Avastin R 60 myelodysplastic syndromes MDS 60 IRESSA 60 recombinant tissue plasminogen 60 colorectal carcinoma 60 sarcomatoid 60 leukemia lymphoma multiple myeloma 60 capecitabine Xeloda 60 Navelbine ® 60 glioblastoma multiforme GBM 60 FOLFOX6 chemotherapy regimen 60 acute promyelocytic leukemia APL 60 SPRYCEL ® 60 Bevacizumab 60 invasive candidiasis 60 gefitinib 60 Onrigin 60 multi kinase inhibitor 60 refractory Hodgkin lymphoma 60 lung cancer NSCLC 60 basiliximab 60 sarcoma melanoma 60 receptor tyrosine kinase inhibitor 60 myelodysplastic syndrome MDS 60 Thiarabine 60 CTEPH 60 PROLARIS 60 taxane therapy 60 grade glioma 60 nasopharyngeal cancer 60 antimetabolite 60 azacytidine 60 relapsing multiple sclerosis 60 Natalizumab 60 Hycamtin ® 60 arthritis PsA 60 ThermoDox R 60 Eculizumab 60 KRAS mutant 60 breast pancreatic 60 postoperative pathology 60 fluorouracil 60 Hodgkin lymphoma HL 60 immunodeficiency disorders 60 chronic thromboembolic pulmonary 60 Waldenstrom macroglobulinemia 60 thymic carcinoma 60 BCG refractory carcinoma 60 metastatic relapsed 60 adenomatous 60 BRCA deficient 60 IMiDs ® compound 60 Zolinza 60 irinotecan containing 60 vinorelbine 60 multiple myeloma MM 60 paclitaxel Taxol ® 60 peritoneal cancer 60 HBeAg negative patients 60 MGd 60 Fludara 60 ovarian breast 60 dermatofibrosarcoma protuberans 60 registrational Phase 60 bronchogenic carcinoma 60 Patients Treated With 60 myelofibrosis MF 60 XIENCE V PROMUS Stent 60 Alemtuzumab 60 TTR amyloidosis 60 Temsirolimus 60 mycosis fungoides 60 Bayer Nexavar 60 Mitomycin C 60 brivanib 60 advanced metastatic prostate 60 Vicinium TM 60 tyrosine kinase inhibitors 60 LungAlert TM 60 GAMMAGARD 60 treat brain aneurysms 60 colorectal lung 60 esophageal gastric 60 MabThera Rituxan 60 crizotinib PF # 60 catheter occlusion 59 predominantly classic subfoveal 59 PI3K/Akt pathway inhibitor 59 familial amyloidotic polyneuropathy FAP 59 antiangiogenic agent 59 stable angina pectoris 59 RECIST Response Evaluation Criteria 59 platinum refractory 59 anthracyclines taxanes 59 pazopanib 59 proteasome inhibitor 59 demonstrated antitumor activity 59 lexidronam injection 59 curative resection 59 ADVEXIN therapy 59 cell lymphoma ALCL 59 Phase #b/#a clinical 59 untreated metastatic pancreatic 59 AVOREN 59 plus prednisone 59 Cimzia TM 59 Brain metastases 59 Eli Lilly Gemzar 59 peginterferon alfa 2a Pegasys 59 Sezary syndrome 59 DU #b 59 allogeneic stem cell 59 cisplatin gemcitabine 59 lung adenocarcinoma 59 non splenectomized 59 distant metastasis 59 monoclonal antibody conjugated 59 Papillary 59 parathyroid carcinoma 59 pediatric malignancies 59 invasive aspergillosis 59 Gleevec imatinib 59 Brentuximab Vedotin SGN 59 pancreatic gastric 59 TheraSphere 59 ZACTIMA TM ZD# 59 invasive lobular 59 Pegasys ® 59 Endologix Powerlink System 59 RoACTEMRA 59 refractory cutaneous T 59 Carcinoid tumors 59 aflibercept VEGF Trap 59 Ceflatonin 59 indolent NHL 59 Vandetanib 59 gemcitabine cisplatin 59 mitoxantrone plus 59 transthyretin amyloidosis 59 malignant growths 59 refractory indolent non 59 TORISEL 59 candidates Azedra TM 59 chronic eosinophilic leukemia 59 mapatumumab 59 acyclovir Lauriad R 59 relapsed refractory multiple myeloma 59 refractory systemic anaplastic 59 Philadelphia Chromosome Positive 59 Chronic lymphocytic leukemia 59 Combination REOLYSIN R 59 metastatic colorectal carcinoma 59 vemurafenib 59 allogeneic hematopoietic stem cell 59 neuroendocrine carcinoma 59 tyrosine kinase inhibitor TKI 59 relapsed Acute Myeloid 59 docetaxel Taxotere 59 FluCAM 59 localized prostate 59 ImClone Erbitux 59 Lymphocytic 59 locoregional 59 thymoma 59 mycophenolate mofetil 59 temsirolimus Torisel ® 59 EOquin TM 59 Refractory Hodgkin Lymphoma 59 malignant lymphoma 59 Allovectin 7 ® 59 Radiofrequency ablation 59 myeloproliferative disorders 59 QuadraSphere 59 anti angiogenic agents 59 INSPIRE Trial Phase III 59 myocardial infarction ventricular fibrillation 59 VeriStrat 59 ximelagatran 59 ixabepilone 59 Flu Cy 59 verteporfin 59 patients undergoing percutaneous 59 skeletal metastases 59 recurrent metastatic ovarian cancer 59 surgically resectable 59 advanced adenomas 59 myelodysplastic syndromes 59 infliximab monotherapy 59 Avastin bevacizumab 59 psoriasis rheumatoid arthritis 59 rheumatoid arthritis RA psoriatic 59 severe hypercholesterolemia 59 Irinotecan 59 Arsenic trioxide 59 Castration Resistant Prostate Cancer 59 histologic subtype 59 TNF Tumor Necrosis Factor 59 recurrent bladder 59 MCSP respectively 59 relapsed GBM 59 Anthracycline 59 castration resistant hormone refractory 59 Mantle Cell Lymphoma 59 histological subtype 59 constipation OIC 59 hepatocellular carcinoma liver 59 induced macular edema 59 histological subtypes 59 pT2 59 Evoltra ® 59 resistant ovarian cancer 59 Syndrome LEMS 59 palliative radiotherapy 59 hepatocellular carcinomas 59 erlotinib Tarceva 59 Previously Untreated 59 humanized interleukin 6 59 Velcade bortezomib 59 PEGylated Fab fragment 59 preoperative chemotherapy 59 VEGFR2 inhibitor 59 endometrial hyperplasia 59 lymphoid malignancies 59 invasive lobular carcinoma 59 malignant pheochromocytoma 59 severe neutropenia 59 acetonide FA 59 cyclophosphamide chemotherapy 59 hematological malignancy 59 refractory CLL 59 herpetic keratitis 59 tiuxetan 59 dasatinib 59 IMiDs ® 59 humanised monoclonal antibody 59 motesanib 59 CBLC# 59 refractory colorectal cancer 59 gastrointestinal GI cancers 59 colorectal breast 59 intestinal metaplasia 59 pegylated liposomal doxorubicin 59 PD LID 59 Myelodysplastic Syndrome MDS 59 Hodgkin lymphoma NHL 59 pegylated alpha interferon 59 resected pancreatic cancer 59 recurrent DVT 59 urothelial carcinoma 59 percutaneous transluminal coronary angioplasty 59 terlipressin 59 Metastatic Renal Cell Carcinoma 59 fluvastatin 59 squamous cell histology 59 Canvaxin 59 epithelial ovarian 59 accumulate preferentially 59 urothelial cancer 59 Rituxan rituximab 59 Alessandro Riva 59 OncoVEX GM CSF 59 hormone refractory prostate cancer 59 renal tumors 59 DOXIL 59 cytologically confirmed 59 PNP inhibitor 59 pT3 59 alvespimycin 59 Gefitinib 59 BAY #-# 59 intracavitary 59 evaluating REVLIMID 59 MyVax R 59 neratinib 59 taxane resistant 59 anastrazole 59 anaplastic astrocytoma 59 tyrosine kinase inhibitors TKIs 59 undergone radical prostatectomy 59 mCRC patients 59 Medullary Thyroid Cancer 59 reslizumab 59 transthoracic 59 malignant pleural mesothelioma MPM 59 Vectibix 59 lung metastases 59 Radiation Therapy SIRT 59 ovarian lung 59 metaglidasen 58 PDX pralatrexate 58 T#I [002] 58 KRAS mutations 58 Glioblastoma Multiforme 58 Xanafide 58 Renal Cell Carcinoma 58 phase IIb clinical 58 XELOX 58 Idiopathic Pulmonary Fibrosis 58 EGFR expressing 58 metastatic pancreatic cancer 58 de novo lesions 58 biliary cancer 58 HER2 positive cancers 58 relapsed leukemia 58 sunitinib 58 Randomized Phase II 58 Mitoxantrone 58 Motexafin Gadolinium 58 Novartis Afinitor 58 NAVISTAR R 58 metastatic liver 58 Vitaxin 58 castrate resistant 58 Neoadjuvant 58 tigecycline 58 TAXUS Express Stent 58 deCODE BreastCancer 58 Trastuzumab 58 GVAX Pancreas Vaccine 58 Glioblastoma multiforme GBM 58 neovascular diseases 58 precursor lesions 58 biochemical relapse 58 interferon beta 1a infertility 58 histologically confirmed 58 imatinib mesylate Gleevec 58 Li Fraumeni Syndrome 58 Vidaza R 58 Cetuximab Erbitux 58 Epidermal Growth Factor Receptor 58 imatinib resistant 58 Severe Sepsis 58 Acute Myeloid Leukaemia AML 58 steroid refractory 58 Sutent sunitinib malate 58 Clolar ® 58 alpha folate receptor 58 Atypical Hemolytic Uremic Syndrome 58 5 Fluorouracil 58 metastatic ovarian cancer 58 ISEL 58 sorafenib 58 aplastic anemia AA 58 eribulin mesylate 58 CIMZIA ™ 58 soft tissue sarcomas 58 Hexvix ® 58 BARACLUDE R 58 including eniluracil ADH 58 castration resistant prostate cancer 58 huN# DM1 58 chemotherapeutic regimen 58 radiolabeled TM# 58 CTAP# Capsules 58 bladder cancers 58 malignant ovarian 58 teriflunomide 58 untreated multiple myeloma 58 rheumatoid arthritis psoriatic arthritis 58 LEUKINE 58 nonsquamous histology 58 dependent kinase inhibitor 58 low dose cytarabine 58 metastatic dermatofibrosarcoma protuberans DFSP 58 oral chemotherapeutic agent 58 metastatic colon cancer 58 relapsed acute lymphoblastic 58 etanercept Enbrel 58 EGFR TK 58 Herceptin trastuzumab 58 Roche Xeloda 58 haematologic malignancies 58 estramustine 58 baseline LDH 58 Lupus Nephritis 58 novel VDA molecule 58 alfa 2a 58 refractory acute promyelocytic 58 Pivotal Clinical Trial 58 remission induction 58 RSR# 58 chemoresistant 58 Quinamed 58 PEGINTRON TM 58 YONDELIS 58 EGFR inhibitors 58 aflibercept 58 Novartis AG Gleevec 58 prostate TURP 58 Afatinib 58 Selective Internal 58 vinorelbine tartrate 58 Systemic lupus erythematosus 58 epithelioid 58 cholangiocarcinoma 58 Prolongs Survival 58 metastatic medullary thyroid 58 Cancer Incidence Mortality 58 allogeneic HSCT 58 transthyretin TTR mediated amyloidosis 58 Pirfenidone 58 metastatic ocular 58 mutated KRAS 58 Votrient 58 Acute myeloid leukemia 58 HER2 Positive Breast Cancer 58 AA Amyloidosis 58 gemcitabine Gemzar ® 58 candidemia 58 capecitabine Xeloda R 58 postoperative chemotherapy 58 tuberous sclerosis TS 58 novel histone deacetylase 58 Vidaza azacitidine 58 Sorafenib 58 colorectal pancreatic 58 Sorafenib Nexavar 58 pancreatic prostate 58 descending thoracic 58 Temodar ® 58 hereditary deficiency 58 Adjuvant chemotherapy 58 HER2 negative 58 ® lenalidomide 58 pancreatic lung 58 precancerous cervical lesions 58 advanced NSCLC 58 paclitaxel Taxol R 58 Alkeran 58 CLL SLL 58 stage IIIb 58 psoriatic arthritis PsA 58 hA# 58 DCVax ® Brain 58 asymptomatic metastatic 58 PSMA ADC 58 Azacitidine 58 placebo dexamethasone 58 vWD 58 TRAIL R1 58 vismodegib 58 TO AVOID PREGNANCY WHILE 58 paclitaxel Taxol 58 EGFR mutation 58 chronic ITP patients 58 pan HDAC inhibitor 58 Myelodysplastic syndromes 58 grade cervical intraepithelial 58 angiogenesis inhibitor 58 zalutumumab 58 FOLFOX 58 Crizotinib 58 generation purine nucleoside 58 neuroendocrine tumors 58 Lilly Gemzar 58 cytogenic 58 Study Evaluating 58 CINTREDEKIN BESUDOTOX 58 adult chronic ITP 58 BEXXAR Therapeutic Regimen 58 lung nodules 58 bortezomib Velcade 58 PEGylated anti 58 multicenter Phase II 58 Daclizumab 58 neoadjuvant chemotherapy 58 FOLFOX chemotherapy 58 SCIg 58 transarterial 58 colorectal neoplasms 58 de novo kidney transplant 58 deletion 5q 58 medullary thyroid cancer 58 fibrate drugs 58 Targretin 58 mildly symptomatic 58 drug Treanda 58 R roscovitine CDK cyclin 58 receiving chemoradiation therapy 58 nilotinib 58 Pertuzumab 58 cytotoxic therapy 58 pegfilgrastim 58 BCG refractory 58 pamidronate 58 serous ovarian cancer 58 HBeAg positive patients 58 Trofex 58 osteosarcoma Ewing sarcoma 58 papillary carcinoma 58 AGILECT R 58 Pegintron 58 Novel Oral 58 pegylated interferon alfa 2a 58 Sudhir Agrawal D.Phil 58 untreated metastatic melanoma 58 metastatic CRPC 58 Chronic HCV 58 Taxotere docetaxel 58 gastroesophageal junction 58 Ophena TM 58 Romiplostim 58 pemetrexed Alimta 58 trastuzumab Herceptin R 58 mCRPC 58 ribavirin RBV 58 liver metastasis 58 sipuleucel T 58 invasive fungal infections 58 Insegia 58 luteinizing hormone releasing 58 Diffuse Large B 58 GORE TAG Device 58 posterior uveitis 58 RCW breast cancer 58 HER2 positive 58 surgically resected 58 systemic RNAi therapeutic 58 refractory metastatic colorectal cancer 58 eribulin 58 Host Disease 58 GRASPA ® 58 acute leukemias 58 Advanced Melanoma 58 allogeneic hematopoietic cell 58 coronary stent merged 58 PLX STROKE targeting 58 Vascugel ® 58 arteriovenous malformations 58 Bezielle 57 HER2 overexpression 57 M2 subunit 57 idarubicin 57 Antitumor Activity 57 Omacetaxine 57 renal cell carcinoma 57 microtubule inhibitor 57 nodal metastasis 57 regorafenib 57 ADP receptor antagonist 57 Solid Tumors criteria 57 oncological indications 57 VFEND 57 enzastaurin 57 non squamous histology 57 Hedgehog Pathway Inhibitor 57 cystic fibrosis bronchiectasis 57 HGS ETR1 57 lung adenocarcinomas 57 CANCIDAS 57 Deforolimus 57 ara C 57 oblimersen 57 Leukemias 57 OPAXIO 57 Mg Usa 57 Panzem NCD 57 Aplidin 57 Epirubicin 57 Ceplene/IL-2 57 refractory angina 57 refractory AML 57 intraductal 57 Chronic Lymphocytic Leukemia CLL 57 HGS# 57 pegylated interferon alpha 57 recurrent squamous cell carcinoma 57 oropharyngeal candidiasis OPC 57 non mutated KRAS 57 TNF antagonist 57 hormone LHRH antagonist 57 bexarotene 57 clodronate 57 liposomal amphotericin B 57 infantile onset 57 Metastatic 57 adrenocortical cancer 57 MYLOTARG 57 Gastrointestinal Stromal Tumors 57 decompensated liver disease 57 Azedra 57 BCIRG 57 liver resection 57 Campath alemtuzumab 57 prostate cancer mCRPC 57 Tavocept 57 pancreatic neuroendocrine 57 idiopathic thrombocytopenic purpura ITP 57 visilizumab 57 Newly Diagnosed Multiple Myeloma 57 alkylating agents 57 antiangiogenesis therapies 57 Telatinib 57 Vfend 57 photodynamic treatment